
Sign up to save your podcasts
Or
The antifungal agent Amphotericin B is highly effective against a wide range of deadly fungi and resistance is rare, even after decades of use. But it comes with a virtual guarantee of kidney damage, earning it the nickname “Ampho-terrible.”
Now, a better alternative might be on the way. Fierce Biotech Research’s Helen Floersh spoke with Martin Burke, M.D., Ph.D., a chemistry professor and researcher at the University of Illinois and the founder of antifungal startup Sfunga Therapeutics, to get the story behind the new drug’s design, its path to the clinic and how it could influence the next generation of antimicrobials.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
3.8
88 ratings
The antifungal agent Amphotericin B is highly effective against a wide range of deadly fungi and resistance is rare, even after decades of use. But it comes with a virtual guarantee of kidney damage, earning it the nickname “Ampho-terrible.”
Now, a better alternative might be on the way. Fierce Biotech Research’s Helen Floersh spoke with Martin Burke, M.D., Ph.D., a chemistry professor and researcher at the University of Illinois and the founder of antifungal startup Sfunga Therapeutics, to get the story behind the new drug’s design, its path to the clinic and how it could influence the next generation of antimicrobials.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
226 Listeners
8,578 Listeners
383 Listeners
442 Listeners
1,773 Listeners
1,446 Listeners
124 Listeners
314 Listeners
1,274 Listeners
1,525 Listeners
84 Listeners
29 Listeners
143 Listeners
10 Listeners
74 Listeners